Inventor

TURECEK PETER

AT110 patents

⚠️ This page may combine multiple inventors who share the name “TURECEK PETER”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

TURECEK PETER

BAXTER AG

Pharmaceutical preparation for treating blood coagulation disorders

Stable preparation for the treatment of blood coagulation disorders

Pharmaceutical composition for the treatment of blood coagulation diseases, methods for the production thereof and its use

Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV

Immunotolerant prothrombin complex preparation

Stable blood coagulation inhibitor-free factor vii preparation and method for preparing same

Method for isolation of highly pure von willebrand factor

Pharmaceutical preparation comprising vWF propeptide

Devices and methods for removing pathogens from biological fluids

Pharmaceutical preparation for treating blood coagulation disorders

Pharmaceutical preparation for treating blood coagulation disorders

Pharmaceutical preparation for treating blood coagulation disorders

IMMUNO AG

Hemostyptic and tissue adhesive

Pharmaceutical preparation for treating blood coagulation disorders

Method for isolation of highly pure von Willebrand Factor

Use of von willebrand factor and pharmaceutical formulation

Stable preparation for the treatment of blood coagulation disorders

Method for isolation of highly pure von willebrand factor

Method of producing a virus-safe biological preparation

Method of producing a virus-safe biological preparation

Method of producing a factor VIII preparation

Method for isolation of highly pure von Willebrand Factor

BAXALTA INC

Factor VIII polymer conjugates

Nucleophilic catalysts for oxime linkage

Lyophilized recombinant VWF formulations

Methods of measuring adamts 13 activity

Nucleophilic catalysts for oxime linkage

Methods of measuring ADAMTS 13 activity

Nucleophilic catalysts for oxime linkage

Lyophilized recombinant VWF formulations

BAXTER INT

Polymer-factor VIII-von Willebrand factor-conjugates

Method for testing treatment of ADAMTS13 deficiency

Pegylated factor VIII

Methods for the inactivation of microorganisms in biological fluids, flow through reactors and methods of controlling the light sum dose to effectively inactivate microorganisms in batch reactors

Polymer-von Willebrand factor-conjugates

Methods of testing effectiveness of a treatment for thromobotic thrombocytopenic purpura by measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor

Methods for the inactivation of microorganisms in biological fluids, flow through reactors and methods of controlling the light sum dose to effectively inactivate microorganisms in batch reactors

SIEKMANN JUERGEN

Nucleophilic catalysts for oxime linkage

Blood coagulation protein conjugates

Nucleophilic catalysts for oxime linkage

Materials and methods for conjugating a water soluble fatty acid derivative to a protein

BAXTER HEALTHCARE SA

Factor VIII polymer conjugates

IMMUNO AKTIENGESLLSCHAFT

Pharmaceutical composition for the treatment of blood coagulation diseases, methods for the production thereof and its use

SANQUIN BLOEDVOORZIENING

Factor VII polypeptide having factor VII:C activity

BAXTER INNOVATIONS GMBH

Composition exhibiting a von Willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV

TAKEDA PHARMACEUTICALS CO

Recombinant VWF formulations

DOCKAL MICHAEL

Method for identifying a non-anticoagulant sulfated polysaccharide which enhances blood coagulation dependence on FXI

WEBER ALFRED

Methods for differentiating plasma-derived protein from recombinant protein in a sample

SCHWARZ HANS-PETER

Modified recombinant factor VIII and von Willebrand factor and methods of use

VARADI KATALIN

Methods of measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor and uses thereof